Skip to content

Innovative Approaches for Personalised Cardiovascular Prevention

Innovative Approaches for Personalised Cardiovascular Prevention: Multicenter Randomised Controlled Study and Multidisciplinary Evaluation for a National Health Service (NHS) Implementation

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05883878
Acronym
INNOPREV
Enrollment
1020
Registered
2023-06-01
Start date
2023-07-24
Completion date
2026-05-31
Last updated
2025-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases

Keywords

Coronary Artery Disease (CAD)

Brief summary

The goal of this clinical trial is to study innovative approaches for personalized primary preventive interventions for cardiovascular diseases (CVD) in the population. The main questions it aims to answer are: * efficacy and safety of the intervention * how to implement the interventions in the NHS Participants will be randomized in one of the four parallel arms: * standard of care; * genetic testing for cardiovascular genetic risk (through the cardiovascular Polygenic Risk Score or PRS); * digital intervention with a wearable device and its app; * digital intervention and genetic testing (PRS) The primary outcome we are going to evaluate is the efficacy of returning PRS information of CVD measured at baseline, alone or in combination with the use of a wearable device, on two endpoints: i) change in lifestyle pattern; ii) CVD risk profile modification. The postulated hypothesis is that the achievement of these endpoints is more likely in presence of at least one of the aforementioned interventions than among subjects who receive only traditional risk assessment at baseline, nor respect to subjects receiving traditional risk assessment plus adopting wearable devices.

Detailed description

The trial will consist of four phases: an enrollment phase (T0), a disclosure visit three weeks later (T1), a follow-up visit five months after the disclosure visit (T2), and a final follow-up twelve months from enrollment (T3). Once enrolled (T0), all participants will sign the informed consent form and undergo a comprehensive assessment, which includes: * Completing a questionnaire on socioeconomic status, area of residence, and lifestyle, using the Life's Essential 8 tool \[1\]. The questionnaire will cover smoking status, alcohol consumption, dietary pattern, sleep pattern, and physical activity. Participants will be classified into favorable, intermediate, or unfavorable individual lifestyle patterns according to the Life's Essential 8 score. * Blood analysis will be performed to evaluate the lipid profile, including total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. At T1, a disclosure visit will be conducted to explain the assigned lifestyle category, share the results of the blood tests, and provide information on the expected interventions based on the assigned group. The questionnaire will be administered at T0, T2, and T3. Blood analysis and cardiovascular profile evaluation will be conducted at both T0 and T3

Interventions

GENETICPRS

genetic test for the evaluation of PRS cardiovascular risk

a wearable device connected with its app

Sponsors

University Of Perugia
CollaboratorOTHER
Policlinic Hospital G. Rodolico
CollaboratorOTHER
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
CollaboratorOTHER
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 69 Years
Healthy volunteers
Yes

Inclusion criteria

* high cardiovascular risk based on the SCORE 2 (between 2.5% and 10%) * age between 40 and 69 years

Exclusion criteria

* diabetes. * familiar hypercholesterolemia. * established CVD.

Design outcomes

Primary

MeasureTime frameDescription
Change in the Lifestyle Category12 monthsThe lifestyle category will be measured using the Life's Essential 8 tool. A change will be considered achieved if there is a shift towards a more favorable lifestyle category.
Modification of the Lipid Profile12 monthsWe will evaluate whether there is a change in the lipid profile compared to the baseline value. The modification of the lipid profile can also be considered as an indicator of the modification of the cardiovascular risk profile measured with the SCORE 2 charts.

Countries

Italy

Contacts

Primary ContactStefania Boccia
stefania.boccia@policlinicogemelli.it+390630154396

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026